FOLH1 and prostate carcinoma: Another interesting setting is evaluating the efficacy of 177Lu-PSMA-I&T as a first-line treatment for oligometastatic prostate cancer relapse after prior surgery or external radical radiotherapy for local disease (Table 1, NCT04443062).